Contextlogic Inc. Stock Price, News & Analysis

LogicBio Therapeutics (Nasdaq: LOGC) reported financial results for the year ending December 31, 2021, showcasing a revenue increase to $5.4 million from $3.5 million in 2020, driven by collaboration revenues. R&D expenses rose to $28.2 million, while G&A expenses climbed to $16.2 million, contributing to a net loss of $40.0 million, or $1.24 per share. The company experienced a clinical hold on LB-001 after a serious adverse event, though it resolved. LogicBio maintains a cash position of $53.5 million, projected to fund operations through Q1 2023.

LogicBio Therapeutics (LOGC) announced that the FDA has placed a clinical hold on its Phase 1/2 SUNRISE trial of LB-001, a gene therapy for methylmalonic acidemia (MMA), due to safety concerns following serious adverse events in two pediatric patients. Despite successful dosing of four patients, including two who reported no drug-related issues, the trial's future is uncertain as LogicBio collaborates with the FDA for next steps. The company has suspended guidance on interim data until further clarity is achieved.

LogicBio Therapeutics (Nasdaq:LOGC) announced that CEO Fred Chereau will participate in a fireside chat at the virtual H.C. Wainwright Bioconnect Conference from January 10-13, 2022. The pre-recorded presentation will be available for on-demand viewing starting January 10, 2022, at 7:00 a.m. ET. A webcast of the presentation can be accessed on the company's investors page and will be available for 30 days.

LogicBio specializes in genetic medicine, focusing on genome editing and gene delivery technologies for rare diseases.

LogicBio Therapeutics, a clinical-stage genetic medicine company, updated stakeholders on its SUNRISE Phase 1/2 clinical trial, demonstrating in vivo genome editing in pediatric patients with methylmalonic acidemia. Although a serious adverse event occurred during the trial, the company reported the patient has recovered. LogicBio also nominated a new development candidate, LB-401, for hereditary tyrosinemia type 1, showing promising preclinical results. Additionally, Susan R. Kahn was appointed to the Board of Directors, bringing a wealth of experience in rare disease advocacy.

LogicBio Therapeutics (Nasdaq: LOGC) reported their third quarter financial results for 2021, showing a revenue increase to $2.1 million, up from $0.9 million in Q3 2020. R&D expenses rose to $7.8 million, while G&A expenses increased to $4.3 million, leading to a net loss of $10.2 million or $0.31 per share. The company anticipates announcing interim data from its Phase 1/2 SUNRISE trial for LB-001 in pediatric patients with methylmalonic acidemia by year-end. LogicBio holds $59.6 million in cash, funding operations into Q4 2022.

LogicBio Therapeutics (Nasdaq:LOGC) announced its president and CEO, Frederic Chereau, will participate in two upcoming investor conferences. The Barclays Gene Editing & Gene Therapy Summit features a fireside chat on November 15, 2021, at 8:00 a.m. ET. The Jefferies Virtual London Healthcare Conference will have a pre-recorded presentation available starting at 3:00 a.m. ET on November 18, 2021. Both events will be accessible via the Company’s website for 30 days. LogicBio focuses on genetic medicine targeting rare diseases with innovative gene editing and delivery technologies.

LogicBio Therapeutics (Nasdaq: LOGC) presented preclinical data on its GeneRide™ platform at the ESGCT Virtual Congress 2021, showcasing its potential in treating methylmalonic acidemia, hereditary tyrosinemia type 1, and Wilson disease. Findings indicated successful repopulation of diseased livers with corrected hepatocytes, demonstrating reduced toxic metabolite levels and improved liver function. The research highlights GeneRide's selective advantage in liver editing, with important implications for genetic medicine. Additional advancements in the company's AAV technology were also discussed.

LogicBio Therapeutics announced promising results from its Phase 1/2 SUNRISE clinical trial, showcasing the first-ever in vivo genome editing in children with methylmalonic acidemia (MMA). The early data indicated measurable levels of the albumin-2A biomarker, confirming gene insertion and protein expression. Based on the independent Data Safety Monitoring Board's recommendation, the trial will proceed to higher dosing cohorts. LB-001, the investigational therapy utilizing GeneRide™ technology, aims to offer a safe, effective treatment for MMA, a rare genetic disorder with no current therapies.

LogicBio Therapeutics (Nasdaq: LOGC) announced its selection to present new data from the GeneRide™ platform at the European Society of Gene and Cell Therapy (ESGCT) Virtual Congress 2021, occurring from October 19-22, 2021. The company will deliver a plenary oral presentation on preclinical data showing effective gene delivery in liver conditions, emphasizing the advantages in corrected hepatocyte repopulation. Additionally, three poster presentations will focus on advancements in treating Tyrosinemia Type 1 and optimizing AAV manufacturing processes.